The role of combination medical therapy in acromegaly: Hope for the nonresponsive patient

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 4, 2013, Pages 321-329

  Fleseriu, Maria ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

acromegaly; combination therapy; dopamine agonists; growth hormone receptor antagonist; somatostatin receptor ligands

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; GESTAGEN; GLUCOSE; GROWTH HORMONE; INSULIN; OCTREOTIDE; PEGVISOMANT; PROLACTIN; RALOXIFENE; SOMATOMEDIN C; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR LIGAND; TAMOXIFEN; UNCLASSIFIED DRUG;

ACROMEGALY; CARDIOMYOPATHY; CELL PROLIFERATION; DIET RESTRICTION; DIMERIZATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GROWTH HORMONE RELEASE; HUMAN; HYPOTENSION; INSULIN BLOOD LEVEL; MONOTHERAPY; NAUSEA; PERSONAL EXPERIENCE; PROLACTIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; REVIEW; TRANSIENT LIVER ENZYME ELEVATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; VALVULAR HEART DISEASE;

ACROMEGALY; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; ERGOLINES; HUMAN GROWTH HORMONE; HUMANS; LIGANDS; RECEPTORS, SOMATOSTATIN;

EID: 84880303531     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e32836318a1     Document Type: Review

References (65)

1. Melmed S. Medical progress: acromegaly. N Engl J Med 2006; 355:2558-2573.
2. Schneider HJ, Sievers C, Saller B, et al. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endo-crinol (Oxf) 2008; 69:432-435.
3. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010; 72:377-382.
4. Rosario PW, Calsolari MR. Screening for acromegaly by application of a simple questionnaire evaluating the enlargement of extremities in adult patients seen at primary healthcare units. Pituitary 2012; 15:179-183.
5. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009; 94:1509-1517.
6. Sughrue ME, Chang EF, Gabriel RA, et al. Excess mortality for patients with residual disease following resection of pituitary adenomas. Pituitary 2011; 14:276-283.
7. Fleseriu M, Delashaw JB Jr, Cook DM. Acromegaly: a review of current medical therapy and new drugs on the horizon. Neurosurg Focus 2010; 29:E15.
8. Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2012. [Epub ahead of print].
9. Mathioudakis N, Salvatori R. Management options for persistent postopera-tive acromegaly. Neurosurg Clin N Am 2012; 23:621-638.
10. Plockinger U. Medical therapy of acromegaly. Int J Endocrinol 2012; 2012:268957.
11. Jane JA Jr, Starke RM, Elzoghby MA, et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab 2011; 96:2732-2740.
12. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008; 93:2957-2968.
13. Brzana J, Yedinak CG, Gultekin SH, et al. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 2012. [Epub ahead of print].
14. Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol (Oxf) 2009; 70:757-768.
15. Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007; 66:859-868.
16. Melmed S, Cook D, Schopohl J, et al. Rapid and sustained reductionof serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multi-center study with a 52 week open extension. Pituitary 2010; 13:18-28.
17. Colao A, Bronstein M, Freda P, et al. Pasireotide LAR is significantly more effective than octreotide LAR at inducing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, Phase III study. Endocrine Abstracts; Presented at Society for Endocrinology ICE/ECE, Florence, Italy 2012; p. OC1.1.
18. Fleseriu M, Sheppard M, Bronstein M, et al. Pasireotide LAR vs octreotide LAR in patients with acromegaly: double-blind, crossover, extension period to a randomized, double-blind, multicenter, phase III study. Endocrine Abstracts; Presented at Society for Endocrinology ICE/ECE, Florence, Italy 2012; p. P1404.
19. Plockinger U, Hoffmann U, Geese M, et al. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4-and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide nonresponsive tumours. Eur J Endocrinol 2012; 166:223-234.
20. Somm E, Bonnet N, Martinez A, et al. A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J Clin Invest 2012; 122:3295-3306.
21. Verde G, Oppizzi G, Colussi G, et al. Effect of dopamine infusion on plasma levels of growth hormone in normal subjects and in agromegalic patients. Clin Endocrinol (Oxf) 1976; 5:419-423.
22. An JJ, Cho SR, Jeong DW, et al. Antiproliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol 2003; 206: 49-62.
23. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 2011; 96:1327-1335.
24. Lamberts SW, Verleun T, Hofland L, et al. Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. J Clin Endocrinol Metab 1986; 63:1342-1347.
25. Rocheville M, Lange DC, Kumar U, et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000; 288:154-157.
26. Lamberts SW, Zweens M, Verschoor L, et al. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs. J Clin Endocrinol Metab 1986; 63:16-19.
27. Saveanu A, Jaquet P, Brue T, et al. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Mol Cell Endocrinol 2008; 286:206-213.
28. Bulenger S, Marullo S, Bouvier M. Emerging role of homo-and hetero-dimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci 2005; 26:131-137.
29. Jallad RS, Bronstein MD. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology 2009; 90:82-92.
30. Marzullo P, Ferone D, Di Somma C, et al. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1999; 1:115-120.
31. Cozzi R, Attanasio R, Lodrini S, et al. Cabergoline addition to depot soma-tostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004; 61:209-215.
32. Selvarajah D, Webster J, Ross R, et al. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 2005; 152:569-574.
33. Mattar P, Alves Martins MR, Abucham J. Short-and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly. Neuroendocrinology 2010; 92:120-127.
34. Vilar L, Azevedo MF, Naves LA, et al. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary 2011; 14:148-156.
35. Suda K, Inoshita N, Iguchi G, et al. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. Endocr J 2013; 60:507-515.
36. Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009; 12:153-157.
37. Kars M, Delgado V, Holman ER, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008; 93:3348-3356.
38. Freda PU, Reyes CM, Nuruzzaman AT, et al. Cabergoline therapy of growth hormone growth hormone/prolactin secreting pituitary tumors. Pituitary 2004; 7:21-30.
39. Tuvia S, Atsmon J, Teichman SL, et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab 2012; 97:2362-2369.
40. Van Der Lely AJ, Muller A, Janssen JA, et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 2001; 86:478-481.
41. Feenstra J, De Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005; 365:1644-1646.
42. Neggers SJ, De Herder WW, Janssen JA, et al. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 2009; 160:529-533.
43. Neggers SJ, Van Aken MO, Janssen JA, et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 2007; 92:4598-4601.
44. Trainer PJ, Ezzat S, D'Souza GA, et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 2009; 71:549-557.
45. van der Lely AJ, Bernabeu I, Cap J, et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol 2011; 164:325-333.
46. Neggers SJ, van der Lely AJ. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm IGF Res 2011; 21:129-133.
47. Jørgensen JOL, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of Acromegaly with a Somatostatin Analog and a Growth Hormone Receptor Antagonist. J Clin Endocrinol Metab 2005; 90:5627-5631.
48. DeMarinis L, Bianchi A, Fusco A, et al. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in nondiabetic patients with active acromegaly partially resistant to SSA. Pituitary 2007; 10:227-232.
49. Madsen M, Poulsen PL, Orskov H, et al. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. J Clin Endocrinol Metab 2011; 96:2405-2413.
50. Madsen M, Krusenstjerna-Hafstrom T, Moller L, et al. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial. J Clin Endocrinol Metab 2012; 97:1227-1235.
51. Neggers SJ, de Herder WW, Feelders RA, et al. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary 2011; 14:253-258.
52. Murray RD, Kim K, Ren SG, et al. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest 2004; 114:349-356.
53. Leung KC, Doyle N, Ballesteros M, et al. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J Clin Endocrinol Metab 2000; 85:4712-4720.
54. Higham CE, Atkinson AB, Aylwin S, et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab 2012; 97:1187-1193.
55. Bernabeu I, Alvarez-Escola C, Paniagua AE, et al. Pegvisomant and cabergo-line combination therapy in acromegaly. Pituitary 2013; 16:101-108.
56. Dimaraki EV, Symons KV, Barkan AL. Raloxifene decreases serum IGF-I in male patients with active acromegaly. Eur J Endocrinol 2004; 150:481-487.
57. Maiza JC, Castillo-Ros S, Matta M, et al. Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide. Pituitary 2012; 15 (Suppl 1):S23-S27.
58. Shimon I, Barkan A. Estrogen treatment for acromegaly. Pituitary 2012; 15:601-607.
59. Leung KC, Doyle N, Ballesteros M, et al. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci USA 2003; 100:101 6-1021.
60. Attanasio R, Barausse M, Cozzi R. Raloxifene lowers IGF-I levels in acromegalic women. Eur J Endocrinol 2003; 148:443-448.
61. Vallette S, Serri O. Oral estroprogestin: an alternative low cost therapy for women with postoperative persistent acromegaly? Pituitary 2010; 13:311-314.
62. Colao A, Pivonello R, Auriemma RS, et al. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 2007; 157:579-587.
63. Fleseriu M. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary 2011; 14:184-193.
64. Giustina A, Mazziotti G, Torri V, et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One 2012; 7:e36411.
65. Mazziotti G, Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 2010; 13:60-67.